| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/16/2014 | WO2014009152A1 A photoprotective personal care composition |
| 01/16/2014 | WO2014008648A1 A composition comprising reduced glutathione and acetaminophen and preparation method thereof |
| 01/16/2014 | WO2014008582A1 Method of treating wounds with penostin and/or ccn2 |
| 01/16/2014 | WO2014008567A1 Modified peptide, cb receptor ligand, kit, in vitro process for evaluating cb receptor bonds, uses, pharmaceutical composition for modulating cb receptor activity |
| 01/16/2014 | WO2013180537A3 Skin-permeating peptide |
| 01/16/2014 | WO2013177584A3 FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) FOR MODULATING HEMOSTASIS |
| 01/16/2014 | WO2013177432A9 Methods of treating obesity |
| 01/16/2014 | WO2013177231A8 Translocation of non-natural chemical entities through anthrax protective antigen pore |
| 01/16/2014 | WO2013177187A3 Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| 01/16/2014 | WO2013173827A3 Methods and compositions for inhibiting diseases of the central nervous system |
| 01/16/2014 | WO2013168965A3 Vaccine composition for preventing staphylococcus aureus infection |
| 01/16/2014 | WO2013167842A3 Immunogenic composition comprising a peptide derived from vegf and uses of same |
| 01/16/2014 | WO2013136193A3 Methods and compositions for modulating toso activity |
| 01/16/2014 | WO2013131093A9 The use of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer |
| 01/16/2014 | US20140018545 Inhibitors of Dipeptidylpeptidase IV |
| 01/16/2014 | US20140018523 Protein purification |
| 01/16/2014 | US20140018306 Methods and compositions for treating ocular disorders |
| 01/16/2014 | US20140018305 Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration |
| 01/16/2014 | US20140018300 Neuroprotective and neurorestorative methods and compositions |
| 01/16/2014 | US20140018298 Citrate free pharmaceutical compositions comprising anakinra |
| 01/16/2014 | US20140018296 LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY |
| 01/16/2014 | US20140018295 Nasal delivery |
| 01/16/2014 | US20140018293 Minimizing intestinal dysfunction |
| 01/16/2014 | US20140018291 Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| 01/16/2014 | US20140018290 Leptin derivatives |
| 01/16/2014 | US20140018289 New treatments of Hepatitis C virus infection |
| 01/16/2014 | US20140018287 Bridge-helix cap: target and method for inhibition of bacterial rna polymerase |
| 01/16/2014 | US20140017774 Pca3, pca3 genes, and methods of use |
| 01/16/2014 | US20140017328 Particle composition and pharmaceutical composition using particle composition |
| 01/16/2014 | US20140017322 Supramolecular functionalization of graphitic nanoparticles for drug delivery |
| 01/16/2014 | US20140017318 Method to produce a medicinal product comprising a biologically active protein and the resulting product |
| 01/16/2014 | US20140017297 Administration of Growth Factors for the Treatment of CNS Disorders |
| 01/16/2014 | US20140017295 Hemostatic material |
| 01/16/2014 | US20140017273 Albumin-Fused Anti-Angiogenesis Peptides |
| 01/16/2014 | US20140017248 Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection |
| 01/16/2014 | US20140017225 Metalloproteinase-9 oligopeptides and their therapeutic use |
| 01/16/2014 | US20140017224 Novel endolysin |
| 01/16/2014 | US20140017223 Pharmaceutical Compositions Comprising A Pancreatic Enzyme Preparation With Viral Infectivity Reduced Below A Significant Level And Methods Of Preparing And Using The Same |
| 01/16/2014 | US20140017221 Superoxide Dismutase Variants and Methods of Use Thereof |
| 01/16/2014 | US20140017220 Treatment of ophthalmic conditions |
| 01/16/2014 | US20140017214 Methods and compositions for delivery of biologics |
| 01/16/2014 | US20140017212 Methods and compositions for the treatment of lysosomal storage diseases |
| 01/16/2014 | US20140017208 Glp-1 receptor agonists for islet cell transplantation |
| 01/16/2014 | US20140017204 Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity |
| 01/16/2014 | US20140017201 Viral vectors for the treatment of retinal dystrophy |
| 01/16/2014 | US20140017195 Hepatitis C Virus Inhibitors |
| 01/16/2014 | US20140017193 Methods for treating nervous system injury and disease |
| 01/16/2014 | US20140017170 Methods and compositions for localized agent delivery |
| 01/15/2014 | EP2684950A1 Pegylated analogue protein of canine urate oxidase, preparation method and use thereof |
| 01/15/2014 | EP2684889A2 Multivariable antigens complexed with targeting humanized monoclonal antibody |
| 01/15/2014 | EP2684575A2 Method for inducing in vivo migration of stem cell |
| 01/15/2014 | EP2684570A1 Compositions and methods for the prevention of oxidative degradation of proteins |
| 01/15/2014 | EP2684569A1 A composition for treatment of advanced prostate cancer |
| 01/15/2014 | EP2684568A2 EEF2-derived peptides for the treatment or prevention of cancer |
| 01/15/2014 | EP2684558A1 Skin-beautifying agent |
| 01/15/2014 | EP2683403A1 Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| 01/15/2014 | EP2683399A2 Methods for diagnosing and/or treating sterility |
| 01/15/2014 | EP2683398A1 Compositions, methods and uses for radioprotectants |
| 01/15/2014 | EP2683397A1 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| 01/15/2014 | EP2683396A1 Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| 01/15/2014 | EP2683395A1 Use of low dose il-2 for treating autoimmune - related or inflammatory disorders |
| 01/15/2014 | EP2683394A2 Active agent prodrugs with heterocyclic linkers |
| 01/15/2014 | EP2683393A2 Tripeptide compositions and methods for treatment of diabetes |
| 01/15/2014 | EP2683389A1 Methods and compositions relating to mesenchymal stem cell exosomes |
| 01/15/2014 | EP2683382A2 Dosing regimens for the treatment of fabry disease |
| 01/15/2014 | EP2683368A1 Treatment of disorders with altered vascular barrier function |
| 01/15/2014 | EP2683364A2 Stable formulations for parenteral injection of peptide drugs |
| 01/15/2014 | EP2683360A1 Pegylated apelin and uses thereof |
| 01/15/2014 | EP2683357A2 Method for cosmetically treating caspase-14 deficiency |
| 01/15/2014 | EP1037926B1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/15/2014 | CN103517712A Neuropeptide analogs, compositions, and methods for treating pain |
| 01/15/2014 | CN103509809A Branchiostoma belcheri chitin-binding associated serine protease CASP gene for identifying chitin and application thereof |
| 01/15/2014 | CN103509121A FSH (follicle-stimulating hormone) fusion protein, and preparation method and application thereof |
| 01/15/2014 | CN103509119A Recombinant fusion protein of short peptide hormone and recombinant pseudomonas exotoxin A and application thereof |
| 01/15/2014 | CN103509118A Insulin-Fc fusion protein |
| 01/15/2014 | CN103509100A Interleukin-1acceptor antagonist mutant |
| 01/15/2014 | CN103509085A Conjugate of androstane and RGD, synthesis thereof, anti-osteoporosis activity thereof, and application thereof |
| 01/15/2014 | CN103508077A Medicine packaging system and kit for intravenous administration |
| 01/15/2014 | CN103505744A Gene delivery system of targeting brain capillary endothelial cell |
| 01/15/2014 | CN103505726A Clinical scientific research formula for heart disease |
| 01/15/2014 | CN103505722A Application of interferon in treating/preventing tumors with resistance to conventional antineoplastic therapies, and related product and method |
| 01/15/2014 | CN103505721A Method of treating myasthenia gravis |
| 01/15/2014 | CN103505720A Application of apolipoprotein A-I in preparation of medicine used for preventing and treating liver disease metabolic syndrome |
| 01/15/2014 | CN103505719A Novel use of S100 calcium binding protein A11 for preparation of drug for relaxing airway smooth muscle |
| 01/15/2014 | CN103505718A Compstatin and analogs thereof for eye disorders |
| 01/15/2014 | CN103505717A Composition containing mushroom mycelium polysaccharides and applications thereof |
| 01/15/2014 | CN103505424A Preparation method for bortezomib for injection |
| 01/15/2014 | CN102964427B Bioactive polypeptide QEPVL, and preparation and application thereof |
| 01/15/2014 | CN102885304B BMD (bone mineral density)-increased health food composite and preparation method thereof |
| 01/15/2014 | CN102838669B Valosin fragment, and preparation method and application thereof |
| 01/15/2014 | CN102716465B Pharmaceutical composite for treating tumor and preparation method of pharmaceutical composite |
| 01/15/2014 | CN102558296B Mytilus edulis enzymolysis polypeptide and preparation method and application thereof |
| 01/15/2014 | CN102459402B Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
| 01/15/2014 | CN102423484B Stable cetrorelix medicinal composition and preparation method thereof |
| 01/15/2014 | CN102210630B System and method for preparing nosiheptide premix particles |
| 01/15/2014 | CN102191255B Preparation and application of recombinant plectasin |
| 01/15/2014 | CN101985036B Amyloid- beta (1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof |
| 01/15/2014 | CN101883785B New non-selective somatostatin analogues |
| 01/15/2014 | CN101880670B 植物血红蛋白 Plants hemoglobin |
| 01/15/2014 | CN101824083B C-terminal deletion type p43 protein and application thereof in medicaments for treating tumor |